ASH 2014: High Hodgkin's lymphoma responses for BMS, Merck PD-1 inhibitors
This article was originally published in Scrip
The race between programmed cell death-1 (PD-1) immune checkpoint inhibitors from Bristol-Myers Squibb and Merck & Co continues with promising data for both monoclonal antibodies in Hodgkin's lymphoma, but Bristol-Myers's Opdivo (nivolumab) has an overall response rate (ORR) edge over Merck's Keytruda (pembrolizumab).
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.